menu
    • menu

    Company profile for Imcyse

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Smithfield BioScience transforms bioproducts into trusted, life-saving therapies through safe, reliable U.S.-based manufacturing.

    Virtual Booth

    Contact Supplier

    Quotient Sciences- Molecule to Cure. Fast.

    Virtual Booth

    Contact Supplier

    SWATI - Transforming science into solutions with 60+ years of expertise, global accreditations, and pioneering biotech innovation.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Imcyse is a clinical-stage biopharmaceutical company pioneering the development of a new class of active, specific immunotherapies for the treatment of severe, chronic autoimmune diseases. The Imcyse technology platform has the potential to address a wide range of indications in the vast field of immunology. It is based on the discovery of modified synthetic peptides - ImotopesTM, which specifically block improper immune resp...
    Imcyse is a clinical-stage biopharmaceutical company pioneering the development of a new class of active, specific immunotherapies for the treatment of severe, chronic autoimmune diseases. The Imcyse technology platform has the potential to address a wide range of indications in the vast field of immunology. It is based on the discovery of modified synthetic peptides - ImotopesTM, which specifically block improper immune responses. Thus representing a next generation, potentially curative approach to severe chronic autoimmune diseases for which there is no satisfactory therapeutic alternative.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    ImcyseBelgium Flag
    Country
    Country
    Belgium
    Address
    Address
    GIGA B34 Avenue de l'Hôpital, 1 4000 Sart Tilman
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.imcyse.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Imcyse Announces Completion of Enrollment in Phase 1 Clinical Trial of IMCY-0141
    Imcyse Announces Completion of Enrollment in Phase 1 Clinical Trial of IMCY-0141

    13 Sep 2023

    // ACCESSWIRE

    https://www.accesswire.com/viewarticle.aspx?id=783679&lang=en

    ACCESSWIRE
    13 Sep 2023
    Share Share
    Imcyse Announces Completion of Enrollment in Phase 2 IMPACT Trial of IMCY-0098
    Imcyse Announces Completion of Enrollment in Phase 2 IMPACT Trial of IMCY-0098

    01 Mar 2023

    // ACCESSWIRE

    https://www.accesswire.com/viewarticle.aspx?id=741397&lang=en

    ACCESSWIRE
    01 Mar 2023
    Share Share
    Imcyse Begins Dosing in Adaptive Phase 1/2 Trial of Imotope IMCY-0141
    Imcyse Begins Dosing in Adaptive Phase 1/2 Trial of Imotope IMCY-0141

    13 Apr 2022

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2022/04/13/2421770/0/en/Imcyse-Announces-First-Patient-Dosed-in-Adaptive-Phase-1-2-Clinical-Trial-of-Imotope-IMCY-0141-for-Multiple-Sclerosis.html

    GLOBENEWSWIRE
    13 Apr 2022
    Share Share
    Imcyse to Present at Oppenheimer 32nd Annual Healthcare Conference
    Imcyse to Present at Oppenheimer 32nd Annual Healthcare Conference

    14 Mar 2022

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2022/03/14/2402419/0/en/Imcyse-to-Present-at-Oppenheimer-32nd-Annual-Healthcare-Conference.html

    GLOBENEWSWIRE
    14 Mar 2022
    Share Share
    Imcyse Reports +ve Immune Response from Phase 2 IMPACT Type 1 Diabetes Study
    Imcyse Reports +ve Immune Response from Phase 2 IMPACT Type 1 Diabetes Study

    13 Jan 2022

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2022/01/13/2366270/0/en/Imcyse-Reports-Positive-Immune-Response-from-Interim-Analysis-of-Phase-2-IMPACT-Type-1-Diabetes-Study.html

    GLOBENEWSWIRE
    13 Jan 2022
    Share Share
    Imcyse appoints Gene Mack as Chief Financial Officer
    Imcyse appoints Gene Mack as Chief Financial Officer

    08 Nov 2021

    // PHARMABIZ

    http://www.pharmabiz.com/NewsDetails.aspx?aid=143765&sid=2

    PHARMABIZ
    08 Nov 2021
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search